Lisdexamfetamine Dimesylate

CHEMBL1201178 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

455.6 g/mol

LogP

—

Phase

4

A dimesylate form of lisdexamfetamine with the same therapeutic properties. A prodrug of dextroamphetamine for ADHD and binge eating disorder.

Moleküler Ağırlık

455,6000 g/mol

TPSA

207,00 Å²

Terapötik Alanlar

Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Multiple Sclerosis Obesity Major Depressive Disorder

Etki Mekanizması

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN

InChI

InChI=1S/C15H25N3O.2CH4O3S/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16;2*1-5(2,3)4/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19);2*1H3,(H,2,3,4)/t12-,14-;;/m0../s1

Molecular Formula

C17H33N3O7S2

HBD / HBA

5 / 9

Döndürülebilir Bağlar

8

Ağır Atomlar

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A dimesylate form of lisdexamfetamine with the same therapeutic properties. A prodrug of dextroamphetamine for ADHD and binge eating disorder.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Lisdexamfetamine Dimesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201178. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11597697. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Lisdexamfetamine Dimesylate PillFYI'da

Yapı

Hızlı Veriler

Formül: C17H33N3O7S2
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Lisdexamfetamine Dimesylate

Terapötik Alanlar

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget